Source comparison
Tesamorelin + Ipamorelin Blend: Protocol Comparison
Ipamorelin monotherapy (200–300mcg) Once nightly before bed Ghrelin receptor agonism → acute GH pulse 8–12% above baseline Moderate improvement in deep sleep duration Effective for sleep and recovery; limited body composition impact without GHRH component Tesa
This comparison does not assign a generated winner or score.
- Ipamorelin monotherapy (200–300mcg)
- Once nightly before bed
- Ghrelin receptor agonism → acute GH pulse
- 8–12% above baseline
- Moderate improvement in deep sleep duration
- Effective for sleep and recovery; limited body composition impact without GHRH component
- Tesamorelin monotherapy (1–2mg)
- Once daily (morning or evening)
- GHRH receptor activation → sustained GH elevation
- 15–22% above baseline
- Mild improvement; less pronounced than ipamorelin
- Better IGF-1 response than ipamorelin alone; slower appetite modulation
- Tesamorelin + ipamorelin blend (1mg + 200mcg)
- Once nightly, 30–45 min pre-sleep
- Dual-mechanism: acute pulse + sustained baseline GH
- 18–28% above baseline
- Strongest improvement; synergistic effect on slow-wave sleep
- Optimal for researchers prioritizing both neurological markers and long-term recomposition; requires 6–8 weeks for fat loss
- CJC-1295 + ipamorelin (100mcg + 200mcg)
- 3–5x weekly
- DAC-extended GHRH analog + ghrelin agonism
- 12–18% above baseline
- Moderate; dosing flexibility reduces circadian alignment
- Comparable IGF-1 response but less consistent sleep benefit due to non-daily dosing